Eric A Ross
Overview
Explore the profile of Eric A Ross including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1997
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vandeloo M, Kellen E, Fang C, Ross E, Vancoillie L, Bruckers L, et al.
Cancer Res Commun
. 2025 Jan;
5(2):267-276.
PMID: 39835404
We consider our findings to be highly novel, and to the best of our knowledge, our study is one of the first to investigate associations between age at FFTP and...
2.
Plimack E, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, et al.
Eur Urol
. 2024 Jul;
86(4):297-300.
PMID: 39003201
We previously reported that tumors harboring any one of four gene mutations (ATM, RB1, FANCC, or ERCC2) were likely to respond to neoadjuvant cisplatin-based chemotherapy (NAC), resulting in cancer-free surgical...
3.
Satyal U, Valentine H, Liu D, Slifker M, Lallas C, Trabulsi E, et al.
JCO Precis Oncol
. 2024 Jun;
8:e2300362.
PMID: 38865671
Purpose: There is significant interest in identifying complete responders to neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) to potentially avoid removal of a pathologically benign bladder. However, clinical restaging after...
4.
Parker C, Zhou L, Prabhu V, Lee S, Miner T, Ross E, et al.
Am J Cancer Res
. 2024 Jan;
13(12):6290-6312.
PMID: 38187068
Gastric adenocarcinoma typically presents with advanced stage when inoperable. Chemotherapy options include non-targeted and toxic agents, leading to poor 5-year patient survival outcomes. Small molecule ONC201/TIC10 (TRAIL-Inducing Compound #10) induces...
5.
Laine C, Wee C, Chang S, Cotton D, Chopra V, Williams S, et al.
Ann Intern Med
. 2023 Jul;
176(7):eL230074.
PMID: 37459624
No abstract available.
6.
Bodor J, Patel J, Wakelee H, Levy B, Borghaei H, Pellini B, et al.
Clin Lung Cancer
. 2023 Jul;
24(7):e242-e246.
PMID: 37451930
Introduction: Patients with non-small-cell lung cancer (NSCLC) who have never smoked or have tumors with mutations in EGFR generally derive minimal benefit from single-agent PD-1/PD-L1 checkpoint inhibitors. Prior data indicate...
7.
Jang H, Hostetter G, Macfarlane A, Madaj Z, Ross E, Hinoue T, et al.
Clin Cancer Res
. 2023 Mar;
29(11):2052-2065.
PMID: 36928921
Purpose: On the basis of preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI), we hypothesized that guadecitabine (hypomethylating agent) and atezolizumab [anti-programmed cell death...
8.
Baldwin D, Gigli C, Kwok T, Connelly S, Helstrom J, Ebersole B, et al.
J Biomol Tech
. 2023 Mar;
33(3).
PMID: 36910578
Background: Supply chain disruptions during the COVID-19 pandemic have affected the availability of components for specimen collection kits to detect SARS-CoV-2. Plastic injection molding offers a rapid and cheap method...
9.
Ward W, Hui J, Davis C, Li T, Goel N, Handorf E, et al.
Ann Surg Open
. 2023 Jan;
2(1):e050.
PMID: 36714392
Background: Controversy persists regarding optimal timing of resections in patients with synchronous colorectal liver metastases. Methods: We analyzed 11,814 patients with disseminated colorectal cancer and/or liver metastases who underwent isolated...
10.
Kadariya Y, Sementino E, Shrestha U, Gorman G, White J, Ross E, et al.
Carcinogenesis
. 2022 Nov;
43(12):1137-1148.
PMID: 36355620
Malignant mesothelioma (MM) is an incurable cancer of the serosal lining that is often caused by exposure to asbestos. Therefore, novel agents for the prevention and treatment of this disease...